Home › Therapeutic areas › Oncology › Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (40 companies)

Companies with an active program in Non-Small Cell Lung Cancer.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ACRV Acrivon Therapeutics GI/HepatologyOncology Rare 1 Phase 2 $61.4M 9
AKTS Aktis Oncology Oncology 2 Phase 1 $910M 10
RCUS Arcus Biosciences DermatologyImmunology+1 1 Phase 3 $2.36B 8
AVBP ArriVent BioPharma Oncology 1 Phase 3 $553M 7
BDTX Black Diamond Therapeutics Oncology 2 Phase 2 $82.8M 4
BBOT BridgeBio Oncology Therapeutics Oncology 2 Phase 1 $156M 6
CCCC C4 Therapeutics Oncology 1 Phase 2 $332M 2
CADL Candel Therapeutics Oncology 1 Phase 3 $424M 4
CMPX Compass Therapeutics Oncology 1 Phase 2 $109M 15
CGEN Compugen Oncology 1 Phase 3 $191M 7
CBIO Crescent Biopharma Oncology 1 Phase 2 $507M 10
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 1 NDA Submitted $602M 10
EIKN Eikon Therapeutics Oncology 1 Phase 2 $279M 13
ERAS Erasca Oncology 1 Phase 1 $4.87B 5
EXEL Exelixis CardiovascularOncology 1 Approved $16.7B 23
GNLX Genelux Oncology 1 Phase 3 $96.1M 3
IDYA IDEAYA Biosciences Oncology 1 NDA Submitted $2.65B 15
IMTX Immatics Oncology 2 Phase 3 $958M 8
IMRX Immuneering Oncology 1 Phase 3 $224M 5
IBRX ImmunityBio Infectious DiseaseOncology 1 Approved $6.66B 17
IMCR Immunocore DermatologyInfectious Disease+2 1 Approved $1.44B 12
IMNM Immunome Oncology Rare 1 NDA Submitted $2.03B 9
INBX Inhibrx Biosciences Oncology 1 NDA Submitted $1.10B 6
KAPA Kairos Pharma Oncology 2 Phase 2 $1.9M 12
KZIA Kazia Therapeutics NeurologyOncology Rare 1 Phase 2 $60.7M 13
KURA Kura Oncology MetabolicOncology 1 Approved $688M 13
MAIA MAIA Biotechnology Oncology 1 Phase 3 $77.2M 8
NKTR Nektar Therapeutics DermatologyImmunology+2 1 Phase 3 $1.23B 11
NBP NovaBridge Biosciences OncologyOphthalmology 1 Phase 2 $95.4M 7
NRIX Nurix Therapeutics ImmunologyNeurology+1 1 Phase 3 $1.56B 13
NVCT Nuvectis Pharma HematologyOncology+1 Rare 2 Phase 3 $660M 9
ORIC Oric Pharmaceuticals Oncology 1 Phase 3 $831M 5
PMVP PMV Pharmaceuticals Oncology 1 Phase 2 $92.2M 7
RVMD Revolution Medicines Oncology 3 Approved $35.2B 11
SMMT Summit Therapeutics Oncology 1 NDA Submitted $8.53B 6
SNDX Syndax Pharmaceuticals ImmunologyOncology Rare 1 Approved $822M 7
TNGX Tango Therapeutics Oncology 3 Phase 1 $3.75B 5
VSTM Verastem Oncology 1 Approved $934M 5
XNCR Xencor ImmunologyNeurology+1 Rare 1 Approved $2.59B 28
ZYME Zymeworks OncologyRespiratory 2 Approved $1.78B 12